Intravenous immunoglobulin: Difference between revisions

From Citizendium
Jump to navigation Jump to search
imported>Howard C. Berkowitz
No edit summary
imported>Howard C. Berkowitz
No edit summary
 
Line 1: Line 1:
{{subpages}}
{{subpages}}
{{TOC|right}}
{{TOC|right}}
'''Intravenous  immunoglobulins''', containing primarily [[immunoglobulin G]], are used to treat a variety of diseases associated with decreased or abnormal [[immunoglobulin]] levels. These  include pediatric [[AIDS]]; primary [[hypergammaglobulinemia]], [[severe combined immunodeficiency]] (SCID), neuropathies, [[cytomegalovirus]]  infections in transplant recipients, [[chronic lymphocytic leukemia]]; [[Kawasaki syndrome]], infection in neonates, and [[idiopathic thrombocytic purpura]].
'''Intravenous  immunoglobulin (IVIG)''', containing primarily [[immunoglobulin G]], are used to treat a variety of diseases associated with decreased or abnormal [[immunoglobulin]] levels. These  include pediatric [[AIDS]]; primary [[hypergammaglobulinemia]], [[severe combined immunodeficiency]] (SCID), neuropathies, [[cytomegalovirus]]  infections in transplant recipients, [[chronic lymphocytic leukemia]]; [[Kawasaki syndrome]], infection in neonates, and [[idiopathic thrombocytic purpura]].
==Cytomegalovirus==
==Cytomegalovirus==
Cytomegalovirus in transplant patients may be prevented or treated with intravenous immunoglobulins.
Cytomegalovirus in transplant patients may be prevented or treated with intravenous immunoglobulins.
Line 7: Line 7:
[[Intravenous immunoglobulin]]s may be used for treatment<ref name="pmid7482820">{{cite journal| author=Waid TH, McKeown JW| title=Cytomegalovirus hyperimmune globulin for CMV disease refractory to ganciclovir in renal transplantation. | journal=Transplant Proc | year= 1995 | volume= 27 | issue= 5 Suppl 1 | pages= 46 | pmid=7482820 | doi= | pmc= | url= }} </ref><ref name="pmid2847609">{{cite journal| author=Emanuel D, Cunningham I, Jules-Elysee K, Brochstein JA, Kernan NA, Laver J et al.| title=Cytomegalovirus pneumonia after bone marrow transplantation successfully treated with the combination of ganciclovir and high-dose intravenous immune globulin. | journal=Ann Intern Med | year= 1988 | volume= 109 | issue= 10 | pages= 777-82 | pmid=2847609 | doi= | pmc= | url= }} </ref>; however, it is not clear that either standard immuneglobulin or hyperimmune globulin are effective.<ref name="pmid9535039">{{cite journal| author=Ljungman P, Cordonnier C, Einsele H, Bender-Götze C, Bosi A, Dekker A et al.| title=Use of intravenous immune globulin in addition to antiviral therapy in the treatment of CMV gastrointestinal disease in allogeneic bone marrow transplant patients: a report from the European Group for Blood and Marrow Transplantation (EBMT). Infectious Diseases Working Party of the EBMT. | journal=Bone Marrow Transplant | year= 1998 | volume= 21 | issue= 5 | pages= 473-6 | pmid=9535039 | doi=10.1038/sj.bmt.1701113 | pmc= | url= }} </ref>  [[Intravenous immunoglobulin]]s may be combined with [[antiviral drug]]s.<ref name="pmid20500045">{{cite journal| author=Alexander BT, Hladnik LM, Augustin KM, Casabar E, McKinnon PS, Reichley RM et al.| title=Use of cytomegalovirus intravenous immune globulin for the adjunctive treatment of cytomegalovirus in hematopoietic stem cell transplant recipients. | journal=Pharmacotherapy | year= 2010 | volume= 30 | issue= 6 | pages= 554-61 | pmid=20500045 | doi=10.1592/phco.30.6.554 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=20500045  }} </ref><ref name="pmid2847609">{{cite journal| author=Emanuel D, Cunningham I, Jules-Elysee K, Brochstein JA, Kernan NA, Laver J et al.| title=Cytomegalovirus pneumonia after bone marrow transplantation successfully treated with the combination of ganciclovir and high-dose intravenous immune globulin. | journal=Ann Intern Med | year= 1988 | volume= 109 | issue= 10 | pages= 777-82 | pmid=2847609 | doi= | pmc= | url= }} </ref>
[[Intravenous immunoglobulin]]s may be used for treatment<ref name="pmid7482820">{{cite journal| author=Waid TH, McKeown JW| title=Cytomegalovirus hyperimmune globulin for CMV disease refractory to ganciclovir in renal transplantation. | journal=Transplant Proc | year= 1995 | volume= 27 | issue= 5 Suppl 1 | pages= 46 | pmid=7482820 | doi= | pmc= | url= }} </ref><ref name="pmid2847609">{{cite journal| author=Emanuel D, Cunningham I, Jules-Elysee K, Brochstein JA, Kernan NA, Laver J et al.| title=Cytomegalovirus pneumonia after bone marrow transplantation successfully treated with the combination of ganciclovir and high-dose intravenous immune globulin. | journal=Ann Intern Med | year= 1988 | volume= 109 | issue= 10 | pages= 777-82 | pmid=2847609 | doi= | pmc= | url= }} </ref>; however, it is not clear that either standard immuneglobulin or hyperimmune globulin are effective.<ref name="pmid9535039">{{cite journal| author=Ljungman P, Cordonnier C, Einsele H, Bender-Götze C, Bosi A, Dekker A et al.| title=Use of intravenous immune globulin in addition to antiviral therapy in the treatment of CMV gastrointestinal disease in allogeneic bone marrow transplant patients: a report from the European Group for Blood and Marrow Transplantation (EBMT). Infectious Diseases Working Party of the EBMT. | journal=Bone Marrow Transplant | year= 1998 | volume= 21 | issue= 5 | pages= 473-6 | pmid=9535039 | doi=10.1038/sj.bmt.1701113 | pmc= | url= }} </ref>  [[Intravenous immunoglobulin]]s may be combined with [[antiviral drug]]s.<ref name="pmid20500045">{{cite journal| author=Alexander BT, Hladnik LM, Augustin KM, Casabar E, McKinnon PS, Reichley RM et al.| title=Use of cytomegalovirus intravenous immune globulin for the adjunctive treatment of cytomegalovirus in hematopoietic stem cell transplant recipients. | journal=Pharmacotherapy | year= 2010 | volume= 30 | issue= 6 | pages= 554-61 | pmid=20500045 | doi=10.1592/phco.30.6.554 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=20500045  }} </ref><ref name="pmid2847609">{{cite journal| author=Emanuel D, Cunningham I, Jules-Elysee K, Brochstein JA, Kernan NA, Laver J et al.| title=Cytomegalovirus pneumonia after bone marrow transplantation successfully treated with the combination of ganciclovir and high-dose intravenous immune globulin. | journal=Ann Intern Med | year= 1988 | volume= 109 | issue= 10 | pages= 777-82 | pmid=2847609 | doi= | pmc= | url= }} </ref>


[[Intravenous immunoglobulin]]s may be used for prevention in transplantation patients.<ref name="pmid2821397">{{cite journal| author=Snydman DR, Werner BG, Heinze-Lacey B, Berardi VP, Tilney NL, Kirkman RL et al.| title=Use of cytomegalovirus immune globulin to prevent cytomegalovirus disease in renal-transplant recipients. | journal=N Engl J Med | year= 1987 | volume= 317 | issue= 17 | pages= 1049-54 | pmid=2821397 | doi=10.1056/NEJM198710223171703 | pmc= | url= }} </ref>
IVIG  may be used for prevention in transplantation patients.<ref name="pmid2821397">{{cite journal| author=Snydman DR, Werner BG, Heinze-Lacey B, Berardi VP, Tilney NL, Kirkman RL et al.| title=Use of cytomegalovirus immune globulin to prevent cytomegalovirus disease in renal-transplant recipients. | journal=N Engl J Med | year= 1987 | volume= 317 | issue= 17 | pages= 1049-54 | pmid=2821397 | doi=10.1056/NEJM198710223171703 | pmc= | url= }} </ref>
==Neuropathy==
==Neuropathy==
[[Intravenous immune globulin]] (IVIG) has been reported to improve quality of life in [[inflammatory polyneuropathy]], especially chronic inflammatory demyelinating polyradiculoneuropathy (. <ref>{{citation  
It has been reported to improve quality of life in [[inflammatory polyneuropathy]], especially chronic inflammatory demyelinating polyradiculoneuropathy (. <ref>{{citation  
  | title = Immune Globulin Helpful in Polyradiculoneuropathy
  | title = Immune Globulin Helpful in Polyradiculoneuropathy
  | author =  Merkies ISJ, ''Neurology'' 2009 Apr 14; 72:1337
  | author =  Merkies ISJ
| journal = Neurology
| date = 14 April 2009 | volume = 72 | page = 1337
  | url = http://www.medscape.com/viewarticle/702178}}</ref>  Patient response to IVIG, however, is influenced by a single nucleotide polymorphism in the transient axonal glycoprotein 1 gene (TAG-1)<ref>{{citation  
  | url = http://www.medscape.com/viewarticle/702178}}</ref>  Patient response to IVIG, however, is influenced by a single nucleotide polymorphism in the transient axonal glycoprotein 1 gene (TAG-1)<ref>{{citation  
  | title = Immune Globulin Helpful in Polyradiculoneuropathy
  | title = Immune Globulin Helpful in Polyradiculoneuropathy

Latest revision as of 21:22, 12 April 2011

This article is developing and not approved.
Main Article
Discussion
Related Articles  [?]
Bibliography  [?]
External Links  [?]
Citable Version  [?]
 
This editable Main Article is under development and subject to a disclaimer.

Intravenous immunoglobulin (IVIG), containing primarily immunoglobulin G, are used to treat a variety of diseases associated with decreased or abnormal immunoglobulin levels. These include pediatric AIDS; primary hypergammaglobulinemia, severe combined immunodeficiency (SCID), neuropathies, cytomegalovirus infections in transplant recipients, chronic lymphocytic leukemia; Kawasaki syndrome, infection in neonates, and idiopathic thrombocytic purpura.

Cytomegalovirus

Cytomegalovirus in transplant patients may be prevented or treated with intravenous immunoglobulins.

Intravenous immunoglobulins may be used for treatment[1][2]; however, it is not clear that either standard immuneglobulin or hyperimmune globulin are effective.[3] Intravenous immunoglobulins may be combined with antiviral drugs.[4][2]

IVIG may be used for prevention in transplantation patients.[5]

Neuropathy

It has been reported to improve quality of life in inflammatory polyneuropathy, especially chronic inflammatory demyelinating polyradiculoneuropathy (. [6] Patient response to IVIG, however, is influenced by a single nucleotide polymorphism in the transient axonal glycoprotein 1 gene (TAG-1)[7] It has also been used in Guillain-Barre syndrome.

References

  1. Waid TH, McKeown JW (1995). "Cytomegalovirus hyperimmune globulin for CMV disease refractory to ganciclovir in renal transplantation.". Transplant Proc 27 (5 Suppl 1): 46. PMID 7482820[e]
  2. 2.0 2.1 Emanuel D, Cunningham I, Jules-Elysee K, Brochstein JA, Kernan NA, Laver J et al. (1988). "Cytomegalovirus pneumonia after bone marrow transplantation successfully treated with the combination of ganciclovir and high-dose intravenous immune globulin.". Ann Intern Med 109 (10): 777-82. PMID 2847609[e]
  3. Ljungman P, Cordonnier C, Einsele H, Bender-Götze C, Bosi A, Dekker A et al. (1998). "Use of intravenous immune globulin in addition to antiviral therapy in the treatment of CMV gastrointestinal disease in allogeneic bone marrow transplant patients: a report from the European Group for Blood and Marrow Transplantation (EBMT). Infectious Diseases Working Party of the EBMT.". Bone Marrow Transplant 21 (5): 473-6. DOI:10.1038/sj.bmt.1701113. PMID 9535039. Research Blogging.
  4. Alexander BT, Hladnik LM, Augustin KM, Casabar E, McKinnon PS, Reichley RM et al. (2010). "Use of cytomegalovirus intravenous immune globulin for the adjunctive treatment of cytomegalovirus in hematopoietic stem cell transplant recipients.". Pharmacotherapy 30 (6): 554-61. DOI:10.1592/phco.30.6.554. PMID 20500045. Research Blogging.
  5. Snydman DR, Werner BG, Heinze-Lacey B, Berardi VP, Tilney NL, Kirkman RL et al. (1987). "Use of cytomegalovirus immune globulin to prevent cytomegalovirus disease in renal-transplant recipients.". N Engl J Med 317 (17): 1049-54. DOI:10.1056/NEJM198710223171703. PMID 2821397. Research Blogging.
  6. Merkies ISJ (14 April 2009), "Immune Globulin Helpful in Polyradiculoneuropathy", Neurology 72: 1337
  7. Sobue G et al., Neurology 2009;73:1348-1352,1344-1345, Immune Globulin Helpful in Polyradiculoneuropathy